Study Summary
This is a single arm, open-label, uni-center, phase I study . In this study, Children withCD19+/CD22+ R/R B-cell acute lymphoblastic leukemia or lymphoma will be treated with CAR-T19/CAR-T22 Immunotherapy to determine the safety and efficacy of treatment.
Want to learn more about this trial?
Request More InfoInterventions
CAR-T19/CAR-T22BIOLOGICAL
According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.The recommand dose is 1x10\^5/kg-2.5x10\^8/kg .
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Xiangya Hospital Central South University | Changsha | Hunan | China |